A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dose of Donepezil on Quantified Electroencephalography and Event-Related Potentials in Patients With AD is a PHASE2 clinical asset sponsored by AstraZeneca in Alzheimer´s Disease. SEO and diligence focus: AZD1446, Donepezil, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.